866-997-4948(US-Canada Toll Free)

Small-Cell Lung Cancer - Pipeline Review, H2 2015

Published By :

Global Markets Direct

Published Date : Dec 2015

Category :


No. of Pages : 564 Pages

Small-Cell Lung Cancer - Pipeline Review, H2 2015


Global Markets Directs, Small-Cell Lung Cancer - Pipeline Review, H2 2015, provides an overview of the Small-Cell Lung Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Small-Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Small-Cell Lung Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- The report provides a snapshot of the global therapeutic landscape of Small-Cell Lung Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Small-Cell Lung Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Small-Cell Lung Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Small-Cell Lung Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Small-Cell Lung Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Small-Cell Lung Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


List of Table


Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *

Upcoming Reports

  • AIDS Associated Dementia Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

    Dementia is characterized by a set of symptoms which includes loss of mental abilities such as social abilities, thinking, memory and judgment. Dementia is severe enough to affect an individual’s daily activities and functions accompanied by certain changes in personality. A person with human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) develop severity of dementia, termed as AIDS associated dementia or AIDS D...

  • Global Vaccine Market Analysis and Forecast 2011-2016

    The report contains the global scenario of Vaccine market discussing its details and market figures. The report provides market size and forecast till 2016 for each segment and geography across the globe. It also describes the key influencing factors for the global vaccine market.  The report lists mergers & acquisitions among the major players along with key product developments in the market. The report also provides information a...

  • DNA Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019

    The completion of human genome project resulted in discovery of several human disease causing genes. This discovery has further led to the evolution of DNA diagnostic platforms and resulted in the transformation of DNA diagnostics platforms from a research based activity into a major professional or commercial activity. The transformation is majorly attributed to the rapid pace of technological advances followed by development of robust methodo...